Liraglutide (Saxenda/Victoza)
Overview
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a half-life of approximately 13 hours. Liraglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through hypothalamic GLP-1R activation. It was the first GLP-1 RA approved for chronic weight management.
Key Research Findings
SCALE trials demonstrated 5-8% mean body weight reduction. LEADER trial showed cardiovascular benefit with 13% reduction in MACE in type 2 diabetes patients. FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014).
Subcutaneous injection (daily)
FDA Approved
Interested in Liraglutide (Saxenda/Victoza)?
Find a verified provider experienced with Liraglutide (Saxenda/Victoza) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Liraglutide (Saxenda/Victoza) ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.